Corvus Pharmaceuticals (CRVS) News Today $4.35 +0.21 (+5.07%) Closing price 07/14/2025 04:00 PM EasternExtended Trading$4.30 -0.04 (-1.03%) As of 07/14/2025 05:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRVS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Director Peter A. Thompson Sells 1,176,332 SharesJuly 1, 2025 | marketbeat.comCompanies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In GrowthJune 25, 2025 | finance.yahoo.comCantor Fitzgerald Remains a Buy on Corvus Pharmaceuticals (CRVS)June 14, 2025 | theglobeandmail.comCorvus Nicks up on Releasing Preclinical Trial DataJune 11, 2025 | baystreet.ca3 Penny Stocks Wall Street Sees With 243% UpsideJune 11, 2025 | 247wallst.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Bought by Bank of America Corp DEJune 11, 2025 | marketbeat.comCantor Fitzgerald Estimates CRVS FY2026 EarningsJune 10, 2025 | marketbeat.comSquarepoint Ops LLC Increases Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)June 5, 2025 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest UpdateJune 4, 2025 | marketbeat.comCorvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisJune 4, 2025 | globenewswire.comCorvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare ConferenceMay 28, 2025 | globenewswire.comOMERS ADMINISTRATION Corp Makes New Investment in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)May 22, 2025 | marketbeat.comPoint72 Asset Management L.P. Sells 2,532,718 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)May 20, 2025 | marketbeat.comSphera Funds Management LTD. Acquires New Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)May 18, 2025 | marketbeat.comRTW Investments LP Invests $14.34 Million in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)May 18, 2025 | marketbeat.comBridgeway Capital Management LLC Has $221,000 Stock Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)May 15, 2025 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Raised to "Hold" at StockNews.comMay 14, 2025 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Sold by Schonfeld Strategic Advisors LLCMay 12, 2025 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Bought by Barclays PLCMay 11, 2025 | marketbeat.comCorvus Pharmaceuticals Shares Surge on Study Data Evaluating SoquelitinibMay 10, 2025 | marketwatch.comDeerfield Management Company L.P. Series C Invests $5.35 Million in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)May 10, 2025 | marketbeat.comRaymond James Financial Inc. Invests $583,000 in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)May 10, 2025 | marketbeat.comCorvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expectedMay 9, 2025 | msn.comCorvus Pharmaceuticals shares surge on positive trial resultsMay 9, 2025 | investing.comIs Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030?May 9, 2025 | uk.finance.yahoo.comCorvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s PleasedMay 9, 2025 | msn.comCorvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comCorvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisMay 8, 2025 | globenewswire.com74,307 Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Acquired by Acuta Capital Partners LLCMay 4, 2025 | marketbeat.comForesite Capital Management VI LLC Buys New Stake in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)April 30, 2025 | marketbeat.comCorvus Pharmaceuticals (CRVS) Expected to Announce Earnings on MondayApril 30, 2025 | marketbeat.comCorvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025April 23, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Olympus (OtherOCPNF) and Corvus Pharmaceuticals (CRVS)April 23, 2025 | markets.businessinsider.comVivo Capital LLC Has $11.96 Million Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)April 23, 2025 | marketbeat.comIs Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires?April 22, 2025 | msn.comCorvus Pharmaceuticals Appoints Richard A. van den Broek to Board of DirectorsApril 9, 2025 | globenewswire.comRaymond James Financial Inc. Makes New Investment in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)April 8, 2025 | marketbeat.comHC Wainwright Has Optimistic View of CRVS FY2025 EarningsMarch 29, 2025 | marketbeat.comCorvus Pharmaceuticals: Now At Cruising AltitudeMarch 28, 2025 | seekingalpha.comCorvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising TrialsMarch 28, 2025 | seekingalpha.comHC Wainwright Issues Pessimistic Forecast for CRVS EarningsMarch 28, 2025 | marketbeat.comCORVUS PHARMACEUTICALS Earnings Results: $CRVS Reports Quarterly EarningsMarch 27, 2025 | nasdaq.comCorvus Pharmaceuticals price target raised to $15 from $14 at OppenheimerMarch 27, 2025 | markets.businessinsider.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | insidermonkey.comCorvus Pharmaceuticals (NASDAQ:CRVS) Receives Buy Rating from HC WainwrightMarch 27, 2025 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Issues Quarterly Earnings ResultsMarch 26, 2025 | marketbeat.comInsider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m ProfitMarch 26, 2025 | finance.yahoo.comCorvus Pharmaceuticals reports Q4 EPS (18c), consensus (12c)March 26, 2025 | markets.businessinsider.comEntryPoint Capital LLC Purchases New Shares in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)March 26, 2025 | marketbeat.com Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVS Media Mentions By Week CRVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRVS News Sentiment▼1.870.98▲Average Medical News Sentiment CRVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRVS Articles This Week▼12▲CRVS Articles Average Week Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aurinia Pharmaceuticals News Ardelyx News Enliven Therapeutics News Verve Therapeutics News Niagen Bioscience News Dyne Therapeutics News Cidara Therapeutics News Collegium Pharmaceutical News BGM Group News Pharvaris News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRVS) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
